| Literature DB >> 30390557 |
Yiping Zhang1, Jinjing Lin2, Guangyu Yan3, Wenhui Jin1, Weizhu Chen1, Jipeng Sun1, Longhe Yang1, Mingqing Huang4, Zhuan Hong5.
Abstract
Previous studies have indicated that dietary fucoxanthin is mainly converted into fucoxanthinol (the deacetylated form) in mammals, but the pharmacokinetics of fucoxanthinol remains unknown. In this study, after intravenous (i.v.) and intragastric gavage (i.g.) administration of fucoxanthinol to rats at 0.8 and 20 mg/kg respectively, one-step protein precipitation with methanol was employed to prepared plasma samples, and an accurate and precise liquid chromatography-tandem mass spectroscopy (LC-MS/MS) method was developed to determine fucoxanthinol. Plasma samples were resolved by LC-MS/MS on a reverse-phase SB-C18 column equilibrated and eluted with acetonitrile (A, 0.1% formic acid) and water (B, 0.1% formic acid) (A:B = 92:8, v/v) at a flow rate of 0.5 mL/min and the injection volume was 5 μL. Analytes were monitored by Selected-reaction monitoring in positive electrospray ionization mode. The calibration curves for fucoxanthinol were linear over the range 1.17-300 ng/mL. The inter-day and intra-day accuracy and precision were within 1.55%-7.90%. The method was applied successfully in a pharmacokinetic study of fucoxanthinol and the resulting bioavailability was calculated.Entities:
Keywords: Fucoxanthinol; LC–MS/MS; Metabolite; Pharmacokinetics
Mesh:
Substances:
Year: 2018 PMID: 30390557 DOI: 10.1016/j.jpba.2018.10.033
Source DB: PubMed Journal: J Pharm Biomed Anal ISSN: 0731-7085 Impact factor: 3.935